Freenome

15 articles with Freenome

• 

  Readers' Picks: Top 10 Stories of 2018

  12/28/2018

  As we look back over the year, we noticed some stories just grabbed readers more than others. Here’s a look at the top 10 stories of the year, including job cuts, best-selling drugs, up-and-coming companies,scandals, clinical trials, and more.

• Freenome Unveils Promising Early Data on Colorectal Cancer Screening Test at American College of Gastroenterology Annual Meeting

  10/9/2018

  Freenome is presenting promising early data on its efforts to utilize machine learning to detect colorectal cancer (CRC) at its earliest stages, when treatment is most effective.

• 

  Investor Enthusiasm About Liquid Biopsies Drives Guardant Health IPO to $1.59 Billion Valuation

  10/5/2018

  Guardant Health went on the Nasdaq yesterday under the symbol GH. Shares climbed almost 70 percent on the first day of trading, selling 12.5 million shares at $19 per share in the initial public offering (IPO).
• 

  As Liquid Biopsies Grow, Who's Going to Pay?

  9/20/2018

  Ilan Danieli, chief executive officer and co-founder of Precipio, a company with a liquid biopsy technology, took time to talk to BioSpace about the company and the economics of liquid biopsies.

• Freenome’s IMPACT Advisory Board Brings Strategic Insight and Real-World Experience to AI-Genomics Cancer Tests

  7/12/2018

  Freenome announced the creation of its IMPACT Advisory Board, a group tasked with helping Freenome’s leadership team optimize the company’s short- and long-term strategies, including those for its first commercial launch.

• 

  Top 10 Stories of the First Half of 2018

  7/6/2018

  It’s hard to believe 2018 is half over. There have been plenty of interesting and important stories in the biopharma space this year. Here’s a look at our top 10 stories so far, counting down from 10 to the number one story.

• QIAGEN showcases innovation in NGS solutions for precision medicine at ASCO 2018

  5/31/2018

  QIAGEN N.V. announced a partnership with Freenome, a leading artificial intelligence (AI) genomics company, to accelerate the development and commercialization of next-generation sequencing (NGS) tests to enable precision medicine in cancer treatment.

• Freenome and Biognosys Announce Collaboration to Improve Early-Cancer Detection and Treatment

  4/24/2018

  Freenome’s platform is poised to detect cancer at its earliest stages and help clinicians optimize the next generation of precision therapies.

• 

  What You Need to Know About Freenome

  1/8/2018

  Freenome, headquartered in South San Francisco, is focused on developing a diagnostic test for early detection of cancer and other diseases on the so-called "liquid biopsy," in other words, blood.
• 

  Top 20 Life Science Startups to Watch in 2018

  1/2/2018

  BioSpace is proud to present its NextGen "Class of 2018," a list of 20 up-and-coming life science companies in North America that started up no earlier than 2015.

• Invitae Chairman Randy Scott Joins Freenome Board of Directors

  12/21/2017

  For nearly three decades, Dr. Scott has been an entrepreneur and visionary leader in genomic medicine.

• Freenome Announces Formation of Scientific Advisory Board

  10/19/2017

  Freenome announced the formation of its Scientific Advisory Board (SAB) comprised of leading experts in genomics and machine learning.

• Freenome Announces Series A Extension Led By Section 32

  8/28/2017

• Freenome Appoints Abraham Tzou, M.D. Vice President, Regulatory Affairs

  8/3/2017

• 28-Year Old's Bay Area Startup Freenome Just Landed $65 Million

  3/1/2017